Tag Archives | MDR-TB

Ensuring Sustainable Access to TB Medicines through Inclusion in the Philippine National Formulary

To begin the project, SIAPS helped coordinate regular planning meetings and discussions with the NTP’s Drugs and Supplies Management (DSM) sub-technical working group. SIAPS then facilitated collaboration among the NTP, the PD, WHO, and the GDF.

Read full story · Comments are closed

How can private medicine vendors help fight drug-resistant TB?

Tuberculosis is one of the world’s deadliest diseases, and multi-drug resistant TB has contributed significantly to the growing global threat of antimicrobial resistance. Yet in many of the countries most burdened by the disease, about half of those who have TB see private medicine vendors before any other health care professional. That can compound the […]

Read full story · Comments { 0 }

New hope for treating drug-resistant TB in Swaziland: An interview with Khontile Kunene

 In April 2015, USAID and Janssen Therapeutics officially launched the bedaquiline (BDQ) donation initiative, under which Janssen committed to providing free BDQ to 30,000 patients with multidrug-resistant tuberculosis (MDR-TB) over a four-year period. Along with delamanid, BDQ is one of only two new TB medicines released to the market in over 40 years. These medicines […]

Read full story · Comments { 0 }

Supporting the National Action Plan on MDR-TB

Global partnerships and new models of TB care are crucial to success in the fight against multidrug-resistant tuberculosis (MDR-TB), according to speakers at a panel discussion on the White House National Action Plan for Combating MDR-TB. The plan, which was released in December, aims to treat 35% of all MDR-TB patients in the 10 countries with the highest TB burden […]

Read full story · Comments { 0 }

Georgia: Establishing a drug safety management and monitoring system for bedaquiline and other drugs

In April 2015, USAID and Janssen Therapeutics officially launched the bedaquiline donation initiative, under which Janssen committed to providing free bedaquiline to 30,000 patients with multidrug-resistant tuberculosis (MDR-TB) over a four-year period. Bedaquiline is the first anti-TB medicine to be approved by the U.S. Food and Drug Administration in more than 40 years, and is […]

Read full story · Comments { 0 }

Drug safety and monitoring are key as bedaquiline donation program launches in Georgia

In April 2015, USAID and Janssen Therapeutics officially launched the bedaquiline donation initiative, under which Janssen committed to providing free bedaquiline to 30,000 patients with multidrug-resistant tuberculosis (MDR-TB) over a four-year period. Bedaquiline is the first anti-TB medicine to be approved by the U.S. Food and Drug Administration in more than 40 years, and is […]

Read full story · Comments { 0 }

Nationwide roll-out of QuanTB in Uzbekistan

In September 2015, USAID’s Systems for Improved Access to Pharmaceuticals and Services (SIAPS) helped the Uzbek Ministry of Health (MOH) successfully complete a nationwide roll-out of QuanTB, a tuberculosis (TB) quantification tool. QuanTB is a downloadable desktop tool that transforms complicated calculations into a user-friendly dashboard displaying key information for managing medicines.  By serving as […]

Read full story · Comments { 0 }

SIAPS Speakers Present at 2015 Global Health Mini-University

Three members of the SIAPS team presented at the 2015 Global Health Mini-University, held on Monday, March 2, at the George Washington University’s Cloyd Heck Marvin Center in Washington, DC. SIAPS Technical Associate Shirin Kakayeva presented on multidrug-resistant tuberculosis (MDR-TB) in Central Asia, highlighting the high MDR-TB burden in Tajikistan (13%) and Uzbekistan (23%) in particular. Kakayeva discussed the […]

Read full story · Comments { 0 }

Strengthening the TB pharmaceutical management system and ensuring patients’ uninterrupted access to anti-TB medicines in Uzbekistan

By Shirin Kakayeva, SIAPS Technical Associate and Dr. Archil Salakaia, SIAPS Central Asia Portfolio Manager Uzbekistan is one of 18 high-priority countries in the WHO’s European region, and is among 27 high-burden multidrug-resistant tuberculosis (MDR-TB) countries in the world. As the uninterrupted supply of anti-TB medicines is necessary for the survival of TB patients, pharmaceutical management […]

Read full story · Comments { 0 }

Drug Use Reviews—A Practical Strategy to Ensure the Rational Use of Anti-Tuberculosis Medicines

This manual is intended as to aid national tuberculosis program (NTP) managers, national pharmacovigilance center managers (NPV), tuberculosis (TB) service delivery providers, health care providers (physicians, pharmacists, nurses, public health officers and other health care professionals), academic institute staff, nongovernmental organizations, researchers, and any other staff working in organizations or individuals who are interested or involved in monitoring and improving medicine use to provide high quality treatment for susceptible tuberculosis (DS-TB) and particularly for drug-resistant tuberculosis (DR-TB).

The manual lists and describes the various steps involved to conduct a DUR. It also provides detailed drug information on World Health Organization’s (WHO) recommended medicines for the treatment of DS-TB and DR-TB. Additionally, the manual provides criteria for reviewing medicines used for TB treatment and also some suggested performance benchmarks or targets for illustrative purposes. Generic data collection forms are also included for local adaptation and use.

Most of the recommendations provided in this manual are generic, describe general principles, and provide a comprehensive, step-by-step explanation of:

  1. Developing context specific DUR criteria according to best available evidence
  2. Collecting and analyzing existing available data
  3. Providing feedback and taking action based on DUR findings when indicated
  4. Reviewing the DUR strategy to identify opportunities for program improvement to provide high quality treatment

These guidelines are intended to be modified according to national or regional specific regulations and treatment practices so they can be used by national TB control programs and their administrative divisions.

Read full story · Comments are closed